News | December 31, 2014

Radiation therapy plus tamoxifen does not reduce 5-year recurrence rates

Radiation therapy, clinical trial/study, women's health

Image courtesy of Hologic


December 31, 2014 — A new analysis has found that while clinical trial data support omitting radiation treatments in elderly women with early stage breast cancer, nearly two-thirds of these women continue to receive it. The findings are published in Cancer, a peer-reviewed journal of the American Cancer Society.

Results published in 2004 from a large, randomized clinical trial showed that adding radiation therapy to surgery plus tamoxifen does not reduce 5-year recurrence rates or prolong survival in elderly women with early stage tumors. Despite the findings, many doctors still administer radiation to these patients.

To examine the extent to which elderly women still receive radiation to treat early stage breast cancer, Rachel Blitzblau, M.D., Ph.D., of Duke University, and her colleagues analyzed information from the nation's largest cancer registry, the Surveillance, Epidemiology and End-Results (SEER) database. The investigators identified 40,583 women older than 70 years of age who were treated with lumpectomy from 2000 to 2009. From 2000 to 2004, before the trial results were published, 68.6% of patients received some form of radiation therapy. From 2005 to 2009, 61.7% of patients received such treatment, although there was a shift in the type of radiation therapy used: fewer patients received standard whole breast radiation, and more received a short course of focused radiation treatment. The results indicate that publication of the trial results had only a very small impact on practice patterns.

"Our findings highlight the fact that it may be challenging for practitioners to incorporate clinical trial data that involves omitting a treatment that was previously considered standard of care," said Blitzblau. She noted that there could be many reasons for this, including concern about the relatively short duration of follow-up of five years. "If a treatment regimen has been working well, and data are new, there can be concern that de-escalation of treatment may ultimately be shown to worsen outcomes." However, the medical community as a whole is aware that there is a need for more financially efficient medical care that omits unnecessary treatments.

Longer-term results of the trial that were published last year showed that recurrence rates continued to be low in women who forewent radiation. Blitzbau noted that it will be interesting to see if these findings will have a larger impact on practice patterns.

For more information: www.cancer.org/healthy/informationforhealthcareprofessionals/otherlinks…

 


Related Content

News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
Subscribe Now